- Home
- INSI vs AMRN Comparison
INSI vs AMRN Comparison
Compare INSI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSI
- AMRN
- Stock Information
- Founded
- INSI 1971
- AMRN 1989
- Country
- INSI United States
- AMRN Ireland
- Employees
- INSI N/A
- AMRN N/A
- Industry
- INSI Investment Managers
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- INSI Finance
- AMRN Health Care
- Exchange
- INSI Nasdaq
- AMRN Nasdaq
- Market Cap
- INSI 183.7M
- AMRN 189.2M
- IPO Year
- INSI N/A
- AMRN 1993
- Fundamental
- Price
- INSI $17.11
- AMRN $0.55
- Analyst Decision
- INSI
- AMRN Buy
- Analyst Count
- INSI 0
- AMRN 1
- Target Price
- INSI N/A
- AMRN N/A
- AVG Volume (30 Days)
- INSI 22.0K
- AMRN 1.8M
- Earning Date
- INSI 01-01-0001
- AMRN 02-27-2025
- Dividend Yield
- INSI 4.90%
- AMRN N/A
- EPS Growth
- INSI N/A
- AMRN N/A
- EPS
- INSI N/A
- AMRN N/A
- Revenue
- INSI N/A
- AMRN $241,021,000.00
- Revenue This Year
- INSI N/A
- AMRN N/A
- Revenue Next Year
- INSI N/A
- AMRN N/A
- P/E Ratio
- INSI N/A
- AMRN N/A
- Revenue Growth
- INSI N/A
- AMRN N/A
- 52 Week Low
- INSI $14.28
- AMRN $0.43
- 52 Week High
- INSI $16.40
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- INSI 49.20
- AMRN 60.15
- Support Level
- INSI $16.96
- AMRN $0.43
- Resistance Level
- INSI $17.25
- AMRN $0.49
- Average True Range (ATR)
- INSI 0.26
- AMRN 0.04
- MACD
- INSI 0.02
- AMRN 0.01
- Stochastic Oscillator
- INSI 65.97
- AMRN 88.57
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.